Lidoderm patch placement
Lidoderm Description Lidoderm (lidocaine patch 5%) is comprised of an adhesive material containing 5% lidocaine, which is applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate ( PET) film release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm × 14 cm. Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections Lidocaine is chemically designated as acetamide, 2-(diethylamino)- N-(2,6-dimethylphenyl has an octanol: water partition ratio of 43 at p H 7.4, and has the following structure: Each adhesive patch contains 700 mg of lidocaine (50 mg per gram adhesive) in an aqueous base. It also contains the following inactive ingredients: dihydroxyaluminum aminoacetate, disodium edetate, gelatin, glycerin, kaolin, methylparaben, polyacrylic acid, polyvinyl alcohol, propylene glycol, propylparaben, sodium carboxymethylcellulose, sodium polyacrylate, D-sorbitol, tartaric acid, and urea. Lidoderm - Clinical Pharmacology Pharmacodynamics Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of Lidoderm is sufficient to produce an analgesic effect, but less than the amount necessary to produce a complete sensory block. Pharmacokinetics Absorption The amount of lidocaine systemically absorbed from Lidoderm is directly related to both the duration of application and the surface area over which it is applied. In a pharmacokinetic study, three Lidoderm patches were applied over an area of 420 cm2 of intact skin on the back of normal volunteers for 12 hours. Blood samples were withdrawn for determination of lidocaine concentration during the application and for 12 hours after.
Original Research Highly Accessed Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM International Journal of Nanomedicine 2014, Published Date:.
General Hepatic Disease Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. Allergic Reactions Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine. However, LIDODERM should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain. Non-intact Skin Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of lidocaine from increased absorption. LIDODERM is only recommended for use on intact skin. External Heat Sources Placement of external heat sources, such as heating pads or electric blankets, over LIDODERM patches is not recommended as this has not been evaluated and may increase plasma lidocaine levels. Eye Exposure The contact of LIDODERM with eyes, although not studied, should be avoided based on the findings of severe eye irritation with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns. Carcinogenesis, Mutagenesis, Impairment Of Fertility Carcinogenesis A minor metabolite, 2, 6-xylidine, has been found to be carcinogenic in rats. The blood concentration of this metabolite is negligible following application of LIDODERM. Mutagenesis Lidocaine HC1 is not mutagenic in Salmonella/mammalian microsome test nor clastogenic in chromosome aberration assay with human lymphocytes and mouse micronucleus test. Impairment of Fertility The effect of LIDODERM on fertility has not been studied. Pregnancy Teratogenic Effects Pregnancy Category B LIDODERM (lidocaine patch 5%) has not been studied in pregnancy. Reproduction studies with lidocaine have been.
Medication Uses | How To Use | Side Effects | Precautions | Drug Interactions | Overdose | Notes | Missed Dose | Storage USES: This medication is used to relieve nerve pain after shingles (infection with the herpes zoster virus). This type of pain is called post-herpetic neuralgia. Lidocaine helps to reduce sharp/burning/aching pain as well as discomfort caused by skin areas that are overly sensitive to touch. Lidocaine belongs to a class of drugs known as local anesthetics. It works by causing a temporary loss of feeling in the area where you apply the patch. HOW TO USE: This product should only be applied to healthy, normal skin. Do not apply to skin that is broken or irritated. Dosage is based on your medical condition and response to therapy. Remove the protective liner and apply the patch to the skin area that is most painful. Apply the prescribed number of patches, usually only once a day for up to 12 hours or as directed by your doctor. Do not apply more than 3 patches once a day or leave any patch on for longer than 12 hours in any 24-hour period. If a smaller patch is needed, it may be cut with scissors before the liner is removed. Wash your hands well after each application. Avoid getting this medication in your eyes or mucous membranes (e.g., nose, mouth). If contact with the eyes accidentally occurs, wash your eyes immediately with water and protect them until normal feeling returns. Inform your doctor if your condition does not improve or worsens. Used patches still contain some medication. However, do not reuse them. Fold the used patch with the sticky sides together and discard it out of the reach of children and pets to prevent accidental swallowing or application. Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA Med Watch website or call 1-800- FDA-1088.
Redness, swelling, blisters, or changes in skin color at the site of application may occur. These effects usually disappear within a few minutes or hours. If any of these effects persist or worsen, notify your doctor or pharmacist promptly. If irritation or a burning feeling occurs, remove the patch(es) and do not reapply until the irritation is gone. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: blurred vision, mental/mood changes (e.g., nervousness, confusion drowsiness, dizziness, unusually slow heartbeat. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088 or at Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at. List Lidoderm topical side effects by likelihood and severity.
September 09, 2012 LAS VEGAS, NV— Lidocaine patch 5% is effective and well-tolerated if applied to the face, trunk, or extremities, according to the results of a study in patients with postherpetic neuralgia reported during PAINWeek 2012. Postherpetic neuralgia has the potential to transpire to any bodily location, many times after an acute herpes zoster presence in trigeminal and brachial plexus dermatomes. According to guidelines on postherpetic neuralgia, Lidocaine patch 5% is indicated for as first-line treatment. Compared with systemic therapy, the Lidocaine patch 5% has a low risk of adverse reactions and drug-drug interactions; this may be an advantage when prescribing the agent in complex instances. Matthew Wieman, MD, from Endo Pharmaceuticals Inc., Chadds Ford, PA, and colleagues conducted a post-hoc analysis to determine whether the anatomic location of Lidocaine patch 5% application is associated with variation in measures of efficacy and tolerability for postherpetic neuralgia pain. Investigators analyzed a 4-week, multicenter, open-label study that enrolled patients of all ages with postherpetic neuralgia of ≥1 month duration after onset. Patients were stratified by bodily location: face (including neck trunk (consisting of chest, abdomen, back, or hips and extremities (consisting of arm or leg). Efficacy was measured by the Brief Pain Inventory ( BPI) average pain intensity, ranging from 0 (no pain) to 10 (worst pain imaginable). A total of 332 patients enrolled in the study, of which 203 used the Lidocaine patch 5% for <12 hours daily on a single anatomic site (trunk: n=130; face: n=41; extremities: n=32 their baseline and post-baseline pain score data were then analyzed. BPI average pain significantly improved from baseline in each of the areas (mean score decrease, 1.5–2.04; P<0.004). Patients also reported significant pain relief at all treated.